340B SOLUTION FROM RXPARADIGM Q: What is the primary problem RxParadigm’s Tungsten+PLUS solves? Tungsten+PLUS™ is a transparent platform designed to eliminate 340B duplicate discounts, reconcile
RxParadigm, a leading enterprise-grade platform for end-to-end 340B drug administration, Medicare Maximum Fair Price (MFP) effectuation, and rebate administration, today announced a strategic partnership with
The 340B Drug Pricing Program is vital for safety-net healthcare providers, allowing them to enhance access to medications, reduce medication costs for vulnerable populations, and
RxParadigm’s Tungsten+PLUS technology is a purpose-built, enterprise-grade platform designed to operationalize Medicare Maximum Fair Price (MFP) effectuation and 340B rebate claims adjudication at scale. The
Are you ready for January 1st, 2026? The 340B Rebate Pilot will shift 340B reimbursement from an upfront discount to an after-fact rebate. Let Tungsten+PLUS™ platform
RxParadigm is a pharmacy technology solutions company founded by experts in drug-pricing transparency, rebate administration, and 340B compliance. Powered by the Tungsten+PLUS™ platform and a
RxParadigm, an end-to-end 340B drug administration platform with integrated capabilities to effectuate Medicare Maximum Fair Price (MFP) requirements, announced that its Tungsten+PLUS™ 340B claims platform
RxParadigm today announced its official connection to the Centers for Medicare & Medicaid Services (CMS) Medicare Transaction Facilitator (MTF) as a Third-Party Support Entity (TPSE).